Scientific Foundation
Nicotinamide Adenine Dinucleotide (NAD+) is a fundamental coenzyme present in every living cell, serving as the central electron carrier in oxidative phosphorylation and as an essential substrate for a broad class of regulatory enzymes. Understanding the biochemistry of NAD+ is foundational to appreciating its pharmaceutical significance and the high standards required of its industrial supply chain.
Sirtuins are a family of NAD+-dependent deacetylases that regulate gene expression, mitochondrial biogenesis, and stress resistance. SIRT1 and SIRT3 are particularly active in metabolic tissues, where they deacetylate key enzymes in fatty acid oxidation and the TCA cycle. Elevated NAD+ levels directly activate sirtuin function, creating a biochemical link between cellular energy status and longevity-associated gene regulation.
Poly(ADP-ribose) polymerases (PARPs) consume large quantities of NAD+ during DNA damage response. PARP1, the most abundant isoform, detects single- and double-strand DNA breaks and catalyzes poly-ADP-ribosylation of repair proteins. Maintaining sufficient NAD+ reserves is therefore critical for genomic integrity, particularly in rapidly dividing cells and post-mitotic neurons.
CD38 is a multifunctional enzyme responsible for degrading NAD+ into cyclic ADP-ribose and nicotinamide. Its activity increases significantly with age and chronic inflammation, directly contributing to the age-related decline in cellular NAD+ levels. Selective inhibition of CD38 represents an emerging pharmacological strategy to restore NAD+ homeostasis in aging tissues.
The body synthesizes NAD+ via three principal routes: the de novo pathway from tryptophan (the kynurenine pathway), the Preiss-Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide and nicotinamide riboside (NR). Pharmaceutical-grade NAD+ precursors supplied by NADJPN Life Science are designed to efficiently enter the salvage pathway, maximizing intracellular conversion efficiency.
Research consistently demonstrates that NAD+ levels in human tissues decline by approximately 50% between the ages of 40 and 60. This decline is driven by three converging factors: increased consumption by CD38 (which is upregulated by senescent cells and chronic low-grade inflammation), reduced biosynthetic capacity as tryptophan-to-NAD+ conversion efficiency decreases, and elevated PARP activity in response to age-associated accumulation of DNA damage.
The consequence of this depletion is a cascade of metabolic dysfunction: impaired mitochondrial electron transport chain activity, reduced sirtuin-mediated gene regulation, compromised DNA repair fidelity, and declining capacity for cellular stress response. This positions NAD+ restoration as a scientifically credible strategy in both therapeutic and preventive health frameworks — and explains why pharmaceutical-grade supply with verified purity is non-negotiable for clinical use.
NAD+ supplementation shows neuroprotective potential in Alzheimer's, Parkinson's, and ALS research models by supporting axonal integrity and mitophagy pathways.
Preclinical and early clinical data demonstrate improvements in insulin sensitivity, hepatic fat metabolism, and mitochondrial function in subjects with metabolic syndrome.
High-dose intravenous NAD+ protocols are used in clinical detoxification programs, supporting neurological repair and reducing withdrawal symptom severity.
NAD+ metabolism intersects with cancer biology through PARP-mediated repair mechanisms, positioning it as a relevant cofactor in adjunctive oncology research.
Elite athletic programs incorporate NAD+ precursor supplementation to accelerate muscle recovery, reduce oxidative stress, and sustain peak mitochondrial output.